Calquence + venetoclax + obinutuzumab: Acceptance of regulatory submission for 1L CLL (based on AMPLIFY trial) in 2023 or later (AstraZeneca) - Feb 10, 2022 - FY 2021 Results
Regulatory • Chronic Lymphocytic Leukemia • Hematological Malignancies • Oncology
|